TB-500 and Thymosin Beta-4 are also prohibited by WADA/USADA under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), applicable at all times both in-competition and out-of-competition TB-500 / Thymosin Beta-4 Clinical Trials: The RGN-352 and RGN-259 Programs RegeneRx Biopharmaceuticals has pursued two clinical development programs for Thymosin Beta-4, providing the most substantial human clinical data available for any TB-500-related compound: RGN-352 (Injectable Thymosin Beta-4 for Cardiac Repair): Phase 1 trial (completed): A double-blind, placebo-controlled study enrolled 40 healthy volunteers across four cohorts of 10 subjects each, testing escalating dose levels of intravenous Thymosin Beta-4 administered daily over 14 days
Research demonstrates that both forms increase skin elasticity by 15-25% after 8-12 weeks of consistent use, though injectable therapy shows measurable improvements 2-3 weeks earlier than powder supplements
Within peptide and recovery-focused research models, this combination is referenced in studies involving tissue-repair mechanisms, angiogenesis modelling, and cellular-response investigation
Researchers and biohackers alike have explored its application for accelerating the healing of soft tissues including tendons, ligaments, muscles, skin, blood vessels, and even nerves
Patients from Miami, Miami Beach, Aventura, Sunny Isles Beach, Hollywood, Hallandale Beach, Fort Lauderdale, Boca Raton, Delray Beach, Boynton Beach, West Palm Beach, Jupiter, Plantation, Coral Springs, Davie, Weston, Deerfield Beach, and surrounding communities can discuss peptide therapy options without traveling to the office
Its primary role is to deliver copper, a trace mineral essential for enzymatic processes involved in tissue repair and antioxidant defense